NVO
NVO
stock
N/A
Accuracy
Recent Predictions
Incorrect: 0
Pending: 16
Prediction
Author
Predicted at
Status
Video
Novo Nordisk (NVO) stock price predicted to rebound to $140 per share, representing 169% upside from its current level.
"What I'm going to show you here could be just the beginning of a rebound back to last year's $140 pe..."
Aug 19, 2025
Pending
Novo Nordisk's oral GLP-1 drug application is predicted to be approved by the FDA, making it the first pill form for weight loss drugs on the market.
"If it is approved, and it is the first application that that has been accepted uh by the FDA, if it ..."
Aug 19, 2025
Pending
Novo Nordisk (NVO) stock is predicted to reach a $90 per share price target, representing a 70% return, based on a rerating to a 7x price to sales multiple.
"I do think it gets there... a $90 per share price target on shares of Novo Nordisk... you get that r..."
Aug 19, 2025
Pending
Novo Nordisk stock (NVO) is predicted to rebound to its 2024 high of $140 per share, representing 169% upside.
"could be just the beginning of a rebound back to last year's $140 per share would be 169% upside"
Aug 19, 2025
Pending
Novo Nordisk's GLP-1 pill application is predicted to be approved by the FDA, making it the first pill-form weight loss drug on the market.
"If it is approved, and it is the first application that that has been accepted uh by the FDA, if it ..."
Aug 19, 2025
Pending
Novo Nordisk's 2025 sales growth forecast (currently 8-14%) is predicted to be upgraded due to increased restrictions on compounded drugs, the release of the pill form, and new indications for Wegovy.
"I do believe that with the uh with the compound restrictions with the pill form coming out as well a..."
Aug 19, 2025
Pending
Novo Nordisk (NVO) stock is predicted to reach $90 per share.
"about a $90 per share price target on shares of Novo Nordisk. I do think it gets there."
Aug 19, 2025
Pending
Novo Nordisk is predicted to achieve sustained long-term expansion despite short-term market challenges.
"The market may be focused on short-term challenges, but the long-term trajectory points to sustained..."
Aug 12, 2025
Pending
The competitive challenges faced by Novo Nordisk due to compounded WGOV versions are temporary.
"This headwind is temporary and the underlying fundamentals remain powerful."
Aug 12, 2025
Pending
Novo Nordisk shares have an intrinsic value of $89, based on conservative analyst projections adopted by the author.
"the algorithm give you a valuation of $89 that is the intrinsic value. Okay. And at the current shar..."
Aug 3, 2025
Pending
Novo Nordisk shares have an intrinsic value of $96 if the company sustains a 10% growth rate for years 6-10.
"So if you put in say 10% uh then shares will be worth $96."
Aug 3, 2025
Pending
Novo Nordisk shares have an intrinsic value of $68 even in a worst-case growth scenario (e.g., 10% for Y1-5, 5% for Y6-10, and 4% for Y11-20).
"in the worst case scenario the shares are worth $68 which means at the current share price of $48 is..."
Aug 3, 2025
Pending
Novo Nordisk shares are predicted by the author to double in value within the next two years from the video's publish date.
"In fact, I think it's an easy uh double for me buying the shares in the next couple of years."
Aug 3, 2025
Pending
Novo Nordisk (NVO) stock, currently undervalued by approximately 40% due to short-term negative news, is expected to appreciate in value given its high quality and strong economic moat.
"another stock which I think is pretty high quality that is currently very cheap because of short-ter..."
Jun 26, 2025
Pending
Novo Nordisk will offer its GLP1 drug at a discount through telehealth providers to reach a broader market.
"CNBC reported last month that Novo Nordisk – the drugs manufacturer will make the drug available at ..."
May 21, 2025
Pending
Novo Nordisk is predicted to have significant future growth potential, provided it resolves challenges in manufacturing capacity, insurance coverage, and drug costs, and if no major unforeseen negative side effects emerge.
"this is something that we still think there is so much huge potential with this particular investmen..."
Jun 16, 2024
Pending